Unique ID issued by UMIN | UMIN000000888 |
---|---|
Receipt number | R000000969 |
Scientific Title | Coronary Artery Dysfunction After Stent Implantation and Effect of Aggressive Lipid-lowering Therapy by Statins - Role of Rho-kinase - |
Date of disclosure of the study information | 2007/11/15 |
Last modified on | 2011/06/02 01:12:23 |
Coronary Artery Dysfunction After Stent Implantation and Effect of Aggressive Lipid-lowering Therapy by Statins
- Role of Rho-kinase -
Coronary Dysfunction After Stenting and Aggressive Lipid-lowering
- Role of Rho-kinase -
(CONTRACTION study)
Coronary Artery Dysfunction After Stent Implantation and Effect of Aggressive Lipid-lowering Therapy by Statins
- Role of Rho-kinase -
Coronary Dysfunction After Stenting and Aggressive Lipid-lowering
- Role of Rho-kinase -
(CONTRACTION study)
Japan |
Ischemic heart disease
Cardiology |
Others
NO
To elucidate the effect of 3-month aggressive lipid-lowering therapy by statin on coronary artery dysfunction after stenting.
Others
To elucidate the role of Rho-kinase in coronary dysfunction after stenting.
Confirmatory
Explanatory
Not applicable
Coronary vasospasm after 3-month trial therapy
1) Cardiovascular events (cardiac death, myocardial infarction, revascularization by PCI or CABG)
2) Severity of angina by Canadian Cardiovascular Society (CCS) classification
3) Biomarkers in peripheral and coronary sinus blood
4) Coronary stenosis and plaque phenotype by angiography or intravascular ultrasound (IVUS)
5) Stent re-endothelialization by angioscopy or optical coherence tomography (OCT)
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
Active
YES
NO
Central registration
2
Treatment
Medicine |
Control therapy:
Slow-release nifedipine (Adalat CR) 20/40mg/day or slow-release diltiazem (Herbesser R) 200mg/day if hypotension is a concern.
Lipid-lowering therapy to achieve LDL-Chol<100mg/dl with statins if needed.
Experimental therapy:
Slow-release nifedipine (Adalat CR) 20/40mg/day or slow-release diltiazem (Herbesser R) 200mg/day if hypotension is a concern.
Aggressive lipid-lowering therapy to achieve LDL-Chol<70mg/dl with pitavastatin (Livalo) 2-4mg/day.
20 | years-old | <= |
Not applicable |
Male and Female
1. Patient of coronary heart disease with prior coronary stenting
2. Patient is planned to undergo follow-up coronary angiography
3. LDL-Chol>70mg/dl
4. Written informed consent for this study
1. Patient with unstable angina or acute myocardial infarction
2. History of angiographycally-proven vasospastic angina
3. Contraindication for statins or calcium channel blockers
4. Familial hypercholesterolemia, liver cirrhosis or renal failure on chronic dialysis
5. Contraindication for intracoronary acetylcholine during coronary angiography
200
1st name | |
Middle name | |
Last name | Kenji Sunagawa |
Kyushu University Graduate School of Medical Sciences
Department of Cardiovascular Medicine
3-1-1Maidashi, Higashi-ku, Fukuoka-shi, Fukuoka 812-8582, Japan
092-642-5360
1st name | |
Middle name | |
Last name | Tetsuya Matoba |
Kyushu University Graduate School of Medical Sciences
Department of Cardiovascular Medicine
3-1-1Maidashi, Higashi-ku, Fukuoka-shi, Fukuoka 812-8582, Japan
092-642-5360
matoba@cardiol.med.kyushu-u.ac.jp
Kyushu University Graduate School of Medical Sciences
Department of Cardiovascular Medicine
Kyushu University Graduate School of Medical Sciences
Department of Cardiovascular Medicine
Self funding
Japan
NO
2007 | Year | 11 | Month | 15 | Day |
Unpublished
Completed
2007 | Year | 11 | Month | 03 | Day |
2007 | Year | 11 | Month | 01 | Day |
2011 | Year | 03 | Month | 01 | Day |
2011 | Year | 03 | Month | 01 | Day |
2011 | Year | 07 | Month | 01 | Day |
2007 | Year | 11 | Month | 14 | Day |
2011 | Year | 06 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000969